We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-1.53%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$24.9M
Cap. Flow
+$51.4M
Cap. Flow %
18.29%
Top 10 Hldgs %
95.45%
Holding
23
New
4
Increased
8
Reduced
7
Closed
1
Avg Time Held Equity + Options
2.4 quarters
Top 10 Avg Time Held Equity + Options
1.3 quarters
Top 20 Avg Time Held Equity + Options
2.4 quarters
Avg Time Held Equity only
2.5 quarters
Top 10 Avg Time Held Equity only
1.3 quarters
Top 20 Avg Time Held Equity only
2.4 quarters

Top Buys

Rank Stock Value
1
INZY icon
Inozyme Pharma
INZY
+$25.1M
2
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$22.1M
3
AMWL icon
American Well
AMWL
+$6.55M
4
PLRX icon
Pliant Therapeutics
PLRX
+$1.16M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$875K

Top Sells

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$2.86M
2
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$1.38M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$691K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$456K
5
KZR icon
Kezar Life Sciences
KZR
+$451K

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
2 Communication Services 0.18%
3 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RPTX icon
1
DELISTED
Repare Therapeutics
RPTX
$77.9M 27.7%
2,530,494
+27,086
+1% +$717K
2020 Q2
1 quarter
PLRX icon
2
Pliant Therapeutics
PLRX
$61.7M
$53.3M 18.95%
2,352,291
+46,297
+2% +$1.16M
2020 Q2
1 quarter
INZY icon
3
DELISTED
Inozyme Pharma
INZY
$26.5M 9.44%
+1,009,117
New +$25.1M
2020 Q3
0 quarters
LRMR icon
4
Larimar Therapeutics
LRMR
$267M
$23M 8.18%
1,515,148
– –
2020 Q2
1 quarter
KROS icon
5
Keros Therapeutics
KROS
$231M
$22M 7.81%
569,458
-10,286
-2% -$408K
2020 Q2
1 quarter
FRLN
6
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$20.7M 7.35%
+88,291
New +$22.1M
2020 Q3
0 quarters
AKUS
7
DELISTED
Akouos Inc
AKUS
$19.4M 6.89%
846,397
-128,588
-13% -$2.86M
2020 Q2
1 quarter
ORTX
8
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12M 4.29%
293,119
– –
2019 Q3
4 quarters
AMWL icon
9
American Well
AMWL
$209M
$7.36M 2.62%
+12,418
New +$6.55M
2020 Q3
0 quarters
DTIL icon
10
Precision BioSciences
DTIL
$179M
$6.25M 2.22%
33,828
+1,827
+6% +$363K
2019 Q3
4 quarters
OVID icon
11
Ovid Therapeutics
OVID
$473M
$3.55M 1.26%
618,092
+73,811
+14% +$494K
2019 Q3
4 quarters
CRVS icon
12
Corvus Pharmaceuticals
CRVS
$844M
$2.34M 0.83%
583,232
+219,100
+60% +$875K
2019 Q3
4 quarters
KZR icon
13
DELISTED
Kezar Life Sciences
KZR
$1.19M 0.42%
24,664
-9,433
-28% -$451K
2019 Q3
4 quarters
GTHX icon
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$970K 0.35%
84,000
+40,000
+91% +$660K
2020 Q2
1 quarter
MYOK
15
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$954K 0.34%
7,000
-6,500
-48% -$691K
2019 Q3
4 quarters
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$882K 0.31%
16,000
+3,000
+23% +$191K
2019 Q3
4 quarters
ADVM icon
17
DELISTED
Adverum Biotechnologies
ADVM
$721K 0.26%
7,000
+2,000
+40% +$300K
2020 Q1
2 quarters
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$1.51B
$616K 0.22%
7,500
-5,500
-42% -$456K
2019 Q3
4 quarters
BPMC icon
19
DELISTED
Blueprint Medicines
BPMC
$603K 0.21%
6,500
-5,500
-46% -$424K
2019 Q3
4 quarters
LVGO
20
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$510K 0.18%
3,640
-11,360
-76% -$1.38M
2019 Q3
4 quarters
BLUE icon
21
DELISTED
bluebird bio
BLUE
$432K 0.15%
618
– –
2019 Q3
4 quarters
GBT
22
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$26K 0.01%
+10,000
New +$636K
2020 Q3
0 quarters
COGT icon
23
Cogent Biosciences
COGT
$5.22B
– –
-235,201
Closed -$433K –

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, CHI Advisors held 23 positions worth $281M, up 9.7% from $256M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

CHI Advisors deployed $51.4M of net new capital in Q3 2020, opening 4 new positions and adding to 8 existing holdings. Its largest new stake was Inozyme Pharma: 1,009,117 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Communication Services and Miscellaneous.

On the sell side, the largest reduction was Akouos Inc, an estimated $2.86M trimmed.

  • CHI Advisors's largest Q3 2020 buy was Inozyme Pharma: 1,009,117 shares worth $26.5M.
  • CHI Advisors added most to Pliant Therapeutics in Q3 2020, an estimated $1.16M increase.
  • CHI Advisors's biggest Q3 2020 reduction was Akouos Inc, cutting an estimated $2.86M.
  • CHI Advisors fully exited Cogent Biosciences in Q3 2020, selling an estimated $433K.
  • CHI Advisors's ten largest holdings make up 95% of its $281M portfolio in Q3 2020.
  • CHI Advisors opened 4 new positions and closed 1 in Q3 2020.
  • CHI Advisors's portfolio value rose 9.7% quarter-over-quarter to $281M.

Based on CHI Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.